As backlash mounts in the wake of a disastrous PhIII flop, Eisai goes deeper with 2 new hires
While Biogen buckles under intense criticism for the Phase III failure of aducanumab for Alzheimer’s — triggering a review of what it should focus on next — its longtime neurosciences partner Eisai continues to build its investment in their controversial R&D work.
The biopharma player has recruited a pair of senior execs to join the Alzheimer’s team at Eisai, which stirred a considerable fuss with a ham-handed decision to start a Phase III trial for BAN2401 right after Biogen was forced to try and explain the aducanumab flop — after building their late-stage pipeline around that project.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.